EMA Authorised: Parsabiv (etelcalcetide hydrochloride) — Amgen Europe B.V.

View source ↗

Summary

EMA authorized Parsabiv (etelcalcetide hydrochloride) by Amgen Europe B.V. for secondary hyperparathyroidism. The decision confirms EU marketing authorization f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• Parsabiv (etelcalcetide)

Snippet

Status: Authorised. Therapeutic area: Hyperparathyroidism, Secondary. MAH: Amgen Europe B.V.. Decision date: 16/09/2021